Name: Pomalidomide-PEG5-CO2H
Brand: BOC Sciences
Price: 259 USD
Availability: MadeToOrder

Size

Price

Stock

Quantity

25 mg

$259

In stock

Purity

≥98%

ShelfLife

2 years

Storage

Store at -20°C

IUPACName

3-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid

Synonyms

1-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-oic acid

InChI Key

PMCQLKMOQUEEDR-UHFFFAOYSA-N

InChI

InChI=1S/C26H35N3O11/c30-21-5-4-20(24(33)28-21)29-25(34)18-2-1-3-19(23(18)26(29)35)27-7-9-37-11-13-39-15-17-40-16-14-38-12-10-36-8-6-22(31)32/h1-3,20,27H,4-17H2,(H,31,32)(H,28,30,33)

Canonical SMILES

C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCOCCOCCOCCOCCOCCC(=O)O

Background Introduction

Pomalidomide-PEG5-CO2H is a versatile E3 ligase ligand-linker conjugate designed for use in targeted protein degradation research. As a derivative of pomalidomide, an immunomodulatory drug (IMiD), this molecule incorporates a polyethylene glycol (PEG5) linker and a carboxylic acid functional group (CO2H), enabling convenient conjugation to various target binders. Due to its optimized design and favorable physicochemical properties, Pomalidomide-PEG5-CO2H is widely utilized in the development of novel Proteolysis Targeting Chimeras (PROTACs).

Mechanism

Pomalidomide-PEG5-CO2H functions by recruiting the E3 ligase cereblon (CRBN) through the pomalidomide moiety. The PEG5 chain provides flexibility and optimal spatial arrangement between the E3 ligase ligand and the attached target protein ligand via the carboxylic acid handle. Upon conjugation to a target binder, the resulting PROTAC molecule simultaneously brings the target protein and CRBN into close proximity, initiating ubiquitination of the target protein. This process directs the protein to the proteasome for selective degradation, facilitating targeted protein knockdown at the post-translational level.

Applications

Pomalidomide-PEG5-CO2H is ideal for constructing custom PROTACs for targeted protein degradation in cellular and in vivo studies. Its optimized linker and functional group allow for straightforward conjugation chemistry, making it suitable for medicinal chemistry, drug discovery, and mechanism-of-action studies. Researchers use Pomalidomide-PEG5-CO2H to design PROTAC molecules to degrade disease-related or aberrant proteins, offering new therapeutic strategies for oncology, neurology, immunology, and beyond. This conjugate is a valuable tool for accelerating the development of next-generation small-molecule degraders.

• PEG5 linker improves water solubility and pharmacokinetic properties for enhanced bioavailability in PROTAC development.
• Carboxylic acid terminus facilitates efficient conjugation to target protein ligands, streamlining synthesis of CRBN-based PROTACs.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂